- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital | 2 | Seeking Alpha | ||
| 15.10. | Propanc Biopharma, Inc.: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital | 227 | GlobeNewswire (Europe) | MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100... ► Artikel lesen | |
| 14.10. | Propanc Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Propanc Biopharma meldet nach NASDAQ-Listing finanzielle Trendwende | 1 | Investing.com Deutsch | ||
| 07.10. | Propanc Biopharma reports major financial transformation after Nasdaq listing | 1 | Investing.com | ||
| 07.10. | Propanc Biopharma reports major financial turnaround after Nasdaq uplisting | 1 | Investing.com | ||
| 07.10. | Propanc Biopharma meldet finanzielle Transformation nach NASDAQ-Listing | - | Investing.com Deutsch | ||
| 07.10. | Propanc Biopharma, Inc.: Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy | 155 | GlobeNewswire (Europe) | MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing treatments for recurring... ► Artikel lesen | |
| PROPANC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 29.09. | Propanc Biopharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 17.09. | Propanc receives US patent for proenzyme cancer treatment composition | 2 | Investing.com | ||
| 17.09. | Propanc Biopharma, Inc.: Propanc Biopharma Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office | 2 | GlobeNewswire (USA) | ||
| 02.09. | Propanc Biopharma announces plan to acquire $100 million of Ethereum | 1 | Seeking Alpha | ||
| 02.09. | Propanc Biopharma, Inc.: Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum | 144 | GlobeNewswire (Europe) | MELBOURNE, Australia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients... ► Artikel lesen | |
| 29.08. | D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. in Connection with its $4,000,000 Uplisting | 383 | ACCESS Newswire | NEW YORK CITY, NEW YORK / ACCESS Newswire / August 28, 2025 / On August 19, 2025, Propanc Biopharma, Inc. (Nasdaq:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer... ► Artikel lesen | |
| 25.08. | Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials | 1 | Investing.com | ||
| 25.08. | Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 | 1 | Investing.com | ||
| 25.08. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Shareholder Update | 236 | GlobeNewswire (Europe) | MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients... ► Artikel lesen | |
| 20.08. | Stocks Moving Premarket: NovaBay Pharmaceuticals, Auddia, Propanc Biopharma And Other Gainers & Losers | 382 | AFX News | CANBERA (dpa-AFX) - At 7:15 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 19.08. | Propanc Biopharma closes public offering, uplists to NASDAQ | 4 | Seeking Alpha | ||
| 19.08. | Stocks Moving Premarket: Viking Therapeutics, Flexsteel Industries, Propanc Biopharma, Soligenix And Other Gainers & Losers | 379 | AFX News | CANBERA (dpa-AFX) - At 8.20 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,972 | +1,54 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| AMGEN | 250,70 | -0,08 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| BIOFRONTERA | 2,790 | +4,49 % | Biofrontera trennt sich vom US-Geschäft | Das Leverkusener Biopharma-Unternehmen hat seine amerikanischen Aktivitäten verkauft. Die Transaktion soll Kosten senken und Risiken eliminieren. Doch was bleibt übrig? Klarer Schnitt mit Folgen: Die... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,00 | -0,85 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,502 | -4,56 % | Drei Säulen für starke Renditen: Warum Biotech-Zulieferer jetzt die wahren Gewinner an der Börse sind! | ||
| NOVONESIS | 54,64 | -0,07 % | Novonesis (Novozymes A/S): Noma and Novonesis partner to scale deliciousness | ||
| TEMPUS AI | 77,00 | 0,00 % | AKTIONÄR-Tipp Tempus AI gibt wieder Gas: Frische Kaufempfehlung | Der Megatrend Künstliche Intelligenz (KI) elektrisiert weiterhin die Marktteilnehmer. Mittendrin im KI-Universum: Tempus AI. Der Onkologie-Spezialist hat in den zurückliegenden Monaten einen Lauf gehabt... ► Artikel lesen | |
| GENMAB | 256,60 | -0,08 % | Genmab A/S: Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. | Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) ("Genmab") announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. ("Purchaser")... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| EXACT SCIENCES | 55,80 | +0,40 % | Cathie Wood's ARK ETF adjusts portfolio with major trades in Exact Sciences, Guardant Health | ||
| TME PHARMA | 0,091 | +0,44 % | TME Pharma N.V.: TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase | Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces... ► Artikel lesen | |
| CYTODYN | 0,202 | -0,98 % | CytoDyn Inc.: September 2025 Letter to Shareholders | VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. ("CytoDyn" or the "Company"), I am pleased to share the... ► Artikel lesen | |
| IMMUNIC | 0,670 | +1,52 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in October
01.10.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings |
Das Unternehmen PROPANC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,520 Euro und damit +2,70 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROPANC BIOPHARMA INC finden Sie auf Wallstreet Online.